Search Results - "Pond, G"

C-statistic: A brief explanation of its construction, interpretation and limitations by Caetano, S.J., Sonpavde, G., Pond, G.R.

“…A brief explanation, interpretation and limitations of clinical statistics is presented. Model validation has traditionally been performed by splitting the…”
Get full text

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK by Storozhuk, Y, Hopmans, S N, Sanli, T, Barron, C, Tsiani, E, Cutz, J-C, Pond, G, Wright, J, Singh, G, Tsakiridis, T

“…Background: We examined the potential of metformin (MET) to enhance non-small cell lung cancer (NSCLC) responses to ionising radiation (IR). Methods: Human…”
Get full text

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy by Balitsky, Amaris, Pond, G R, Davies, G A, Fraser, G, Kouroukis, T, Levine, M, Meyer, R M, Foley, R

“…Chimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in refractory and relapsed large B-cell lymphomas, but is associated with serious…”
Get full text

ASO Visual Abstract: Immigration Status and Breast Cancer Surgery Quality of Care Metrics: A Population-Level Analysis by Parvez, E., Bogach, J., Kirkwood, D., Pond, G., Doumouras, A., Hodgson, N., Levine, M.

Get full text

Immigration Status and Breast Cancer Surgery Quality of Care Metrics: A Population-Level Analysis by Parvez, E., Bogach, J., Kirkwood, D., Pond, G., Doumouras, A., Hodgson, N., Levine, M.

“…Introduction As immigrant women face challenges accessing health care, we hypothesized that immigration status would be associated with fewer women with breast…”
Get full text

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials by Templeton, A.J., Vera-Badillo, F.E., Wang, L., Attalla, M., De Gouveia, P., Leibowitz-Amit, R., Knox, J.J., Moore, M., Sridhar, S.S., Joshua, A.M., Pond, G.R., Amir, E., Tannock, I.F.

“…Multiple factors can influence outcomes of patients receiving identical interventions in clinical trials and in routine practice. Here, we compare outcomes of…”
Get full text

Cognitive function and fatigue after diagnosis of colorectal cancer by Vardy, J., Dhillon, H.M., Pond, G.R., Rourke, S.B., Xu, W., Dodd, A., Renton, C., Park, A., Bekele, T., Ringash, J., Zhang, H., Burkes, R., Clarke, S.J., Tannock, I.F.

“…Cognitive impairment and fatigue have been associated with cancer and its treatment. We present baseline data from a large longitudinal study that evaluates…”
Get full text

Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy by Bane, A.L., Whelan, T.J., Pond, G.R., Parpia, S., Gohla, G., Fyles, A.W., Pignol, J.-P., Pritchard, K.I., Chambers, S., Levine, M.N.

“…To determine whether tumor grade, molecular subtype and hypoxia predict response to hypofractionated versus standard radiotherapy (RT) following…”
Get full text

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas by DURAN, I, KORTMANSKY, J, BIRLE, D, POND, G. R, ARBOINE, D, DANCEY, J, AVIEL-RONEN, S, TSAO, M.-S, HEDLEY, D, SIU, L. L, SINGH, D, HIRTE, H, KOCHA, W, GOSS, G, LE, L, OZA, A, NICKLEE, T, HO, J

“…Standard cytotoxic treatments for neuroendocrine tumours have been associated with limited activity and remarkable toxicity. A phase II study was designed to…”
Get full text

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy by VARDY, J, CHIEW, K. S, GALICA, J, POND, G. R, TANNOCK, I. F

“…The role of dexamethasone to reduce delayed emesis following highly emetogenic chemotherapy is proven, but there is less evidence of benefit after…”
Get full text

Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey by Bradbury, M., Savard, MF, Stober, C., Clemons, L., Clemons, M., Hilton, J., Pond, G., Vandermeer, L., McGee, SF

“…Purpose Despite previous studies proposing shorter durations of anti-HER2 therapy for selected patients with HER2-positive early breast cancer (EBC), 12-months…”
Get full text

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab by Blanchette, P. S., Desautels, D. N., Pond, G. R., Bartlett, J. M. S., Nofech-Mozes, S., Yaffe, M. J., Pritchard, K. I.

“…Purpose We have limited capability to predict survival among patients treated for metastatic HER2-positive breast cancer. Further research is warranted to…”
Get full text

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study by Jerzak, K. J., Cockburn, J. G., Dhesy-Thind, S. K., Pond, G. R., Pritchard, K. I., Nofech-Mozes, S., Sun, P., Narod, S. A., Bane, A.

“…Purpose Preliminary data suggest that high expression of the TRβ1 tumor suppressor is associated with longer survival among women with early breast cancer. We…”
Get full text

Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study by Vardy, J.L., Dhillon, H.M., Pond, G.R., Renton, C., Dodd, A., Zhang, H., Clarke, S.J., Tannock, I.F.

“…Fatigue is associated with cancer and chemotherapy and may be sustained. Here, we describe a prospective longitudinal study evaluating fatigue and putative…”
Get full text

Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study by Donovan, E.K., Pond, G.R., Seow, H., Ellis, P.M., Swaminath, A.

“…To assess the risk of cardiac toxicity following radical radiotherapy in advanced lung cancer patients. Patients with a diagnosis of stage III non-small cell…”
Get full text

A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer by Clemons, M., Fergusson, D., Simos, D., Mates, M., Robinson, A., Califaretti, N., Zibdawi, L., Bahl, M., Raphael, J., Ibrahim, M.F.K., Fernandes, R., Pitre, L., Aseyev, O., Stober, C., Vandermeer, L., Saunders, D., Hutton, B., Mallick, R., Pond, G.R., Awan, A., Hilton, J.

“…The optimal duration of filgrastim as primary febrile neutropenia (FN) prophylaxis in early breast cancer patients is unknown, with 5, 7 or 10 days being…”
Get full text

Statistical issues in the use of dynamic allocation methods for balancing baseline covariates by Pond, G R

“…Background: The procedure for allocating patients to a treatment arm in comparative clinical trials is frequently chosen with only minor deliberation. This…”
Get full text

P291 Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers by Beltran-Bless, A.-A., Larocque, G., Arnaout, A., Caudrelier, J.-M., Vandermeer, L., Pond, G., Clemons, M.

Get full text

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa by Berthold, D.R., Pond, G.R., de Wit, R., Eisenberger, M., Tannock, I.F.

“…The TAX 327 study compared 3-weekly docetaxel, weekly docetaxel or 3-weekly mitoxantrone, each with prednisone, for 1006 patients with metastatic…”
Get full text

Oncologists and medical assistance in dying: where do we stand? Results of a national survey of Canadian oncologists by Chandhoke, G, Pond, G, Levine, O, Oczkowski, S

“…In June 2016, when the Parliament of Canada passed Bill C-14, the country joined the small number of jurisdictions that have legalized medical assistance in…”
Get full text